Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cluster headaches

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Independent consultant will review Lilly’s COVID-19 plant issues

COVID-19 antibody trial was paused last week due to safety issue

- PMLiVE

Lilly buys biotech firm Disarm Therapeutics for $135m

Deal could eventually be worth up to $1.36bn

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

- PMLiVE

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The combination treatment hit the primary study endpoint of a reduction in recovery time

- PMLiVE

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Detailed phase 3 results presented at the virtual World Conference on Lung Cancer

- PMLiVE

Eli Lilly begins COVID-19 prevention trial in nursing homes

Trial will investigate monoclonal antibody in up to 2,400 participants

- PMLiVE

Boehringer/Lilly’s Jardiance hits the mark in pivotal heart failure trial

Drug reduced risk of death/hospitalisation in patients with and without diabetes

- PMLiVE

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor

- PMLiVE

Lilly halts most clinical trials as coronavirus disruption continues

Will continue ongoing trials for patients who are already enrolled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links